Market News & Trends
Generex Announces New $11-Million Collaboration
Generex Biotechnology Corporation recently announced that it has entered into a non-binding Letter of Intent (LOI) to license the Generex proprietary RapidMis drug delivery technologies…
Investigational Brain Cancer Vaccine Produces Strong Immunological Response
A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in patients with recurrent or progressive malignant brain tumors, according to results of a…
Dicerna Presents New Data From Multiple Tumor Models
Dicerna Pharmaceuticals, Inc. recently announced promising new in vivo data for CTNNB1 DsiRNA in multiple patient-derived xenograft (PDX) and other models of diverse tumor types.…
Huntingdon Life Sciences & Harlan Laboratories Announce Significant Launch
Huntingdon Life Sciences and Harlan Laboratories recently announced the launch of the SHrN – the world’s first hairless NOD.SCID mouse model to reach the market.…
Deciphera Pharmaceuticals Presents Data Highlighting Kinase Inhibitor Pipeline
Deciphera Pharmaceuticals recently announced that preclinical data on the company’s growing pipeline of next-generation kinase inhibitors were presented at the American Association for Cancer Research…
BIND Therapeutics Presents Positive Data Highlighting Ability of Accurins
BIND Therapeutics, Inc. recently announced that clinical and preclinical data from its oncology pipeline, including proprietary and collaboration programs, were presented at the American Association…
Gx MultiShell Unites the Properties of Glass & Plastic
Every day, millions of people are treated with parenteral medications, such as precautionary vaccinations or injections and infusions for medical conditions. Gerresheimer supplies the pharmaceutical…
Teva's Potential $40-Billion Acquisition Could Transform Generics Space
Teva Pharmaceutical Industries’ recent $40.1-billion offer to purchase Netherlands-based Mylan, which is crucially contingent on Mylan not consummating its offer to acquire Irish firm Perrigo,…
Pipeline Advancements & Asset Acquisitions Fueled Mid-Cap Biotech Research & Development Spend in 2014
The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a…
Q1 2015 Global Pharma, Medical & Biotech Trend Report
Mergermarket has released its Global Pharma, Medical & Biotech (PMB) trend report for the first quarter (Q1) of 2015. Take a look at the full…
New Jersey Pharmaceutical Association for Science & Technology Celebrates 60th Anniversary
The New Jersey Pharmaceutical Association for Science and Technology (NJPhAST) will be launching the celebration of its 60th anniversary at its September 17th meeting…
West Pharmaceutical Services Appoints New CEO
West Pharmaceutical Services, Inc. recently announced that Eric M. Green has been appointed the company's Chief Executive Officer, succeeding Donald E. Morel, Jr., PhD, current…
Catalent Completes $52-Million Expansion
Catalent Pharma Solutions recently announced the opening of a large-scale expansion at its Winchester, KY, manufacturing facility, which has seen the doubling of its footprint…
Aduro Biotech Announces Pricing of IPO; Expects $107 Million
Aduro Biotech, Inc. recently announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of…
Celgene & Mesoblast Enter $45-Million Agreement
Mesoblast Limited recently announced it has entered into an agreement with US-based Celgene Corporation, a global biopharmaceutical company engaged in the development and commercialization of…
Drug R&D Costs: $1.7 Billion & Rising
The significant costs of developing new, life-saving drugs and treatments has reached over $1.7 billion per drug over a span of 10-12 years. The mounting…
Recipharm Makes Strategic Investment in Synthonics
Recipharm recently announced it has made an equity investment in Synthonics Inc and purchased $2 million of preferred stock in the company. A further $2…
Firm Raises $2.8 Billion for NEA 15 Fund; $350 Million for Opportunity Fund
Global venture capital firm New Enterprise Associates, Inc. recently announced the close of its 15th fund with $2.8 billion in committed capital to its core…
Melanoma Treatment Market Value to More Than Quadruple to $5.64 Billion
The global treatment market for melanoma will expand more than four-fold in value from $1.34 billion in 2013 to reach an estimated $5.64 billion by…
Edge Therapeutics Raises $72.5 Million to Advance Pipeline
Edge Therapeutics recently announced it has raised approximately $72.5 million in gross proceeds from two recently completed private financing rounds. The most recent round, a…
